Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

Cyclerion Therapeutics Inc (NASDAQ: CYCN) shares surged 350% following the announcement of a merger with Korsana Biosciences in an all-stock transaction, which will transform Cyclerion into an Alzheimer's-focused biotech company. The merger will result in the new entity operating under the name Korsana Biosciences, trading as KRSA, and is accompanied by a $380 million financing commitment to support clinical milestones through 2029. Cyclerion shareholders are expected to retain only 1.5% of the combined company, indicating the market's enthusiasm is primarily driven by Korsana's drug pipeline.